antidepressant powerpoint on pharmacology
DESCRIPTION
pharmacology understanding on antidepressants in pyschiatry and the ways it affects our neurotransmittersTRANSCRIPT
![Page 1: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/1.jpg)
Antidepressants
![Page 2: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/2.jpg)
Pharmacotherapyu Antidepressantsu Anxiolyticsu Mood stabilizersu Antipsychotics
Psychotherapyu Cognitive behavioral
therapyu Interpersonal therapyu Marital/family counselingu Group therapy
Somatic Therapyu Electroconvulsive therapyu Bright light therapyu Possibly:
F Transcranial magnetic stimulation
F Vagal nerve stimulationF Sleep deprivation
![Page 3: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/3.jpg)
![Page 4: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/4.jpg)
![Page 5: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/5.jpg)
![Page 6: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/6.jpg)
![Page 7: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/7.jpg)
![Page 8: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/8.jpg)
![Page 9: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/9.jpg)
TCA
• block reuptake of NE & 5ST
• major depression, bedwetting, OCD, fibromyagia
![Page 10: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/10.jpg)
TCA SIDE EFFECTSTricyclic Action SE
(-)presynaptic NT (NE/5ST) reuptake tremor, insomnia
Block of cardiac fast Na channels conduction defect, arrythmias, hypotension
antagonism of c/p muscarinic Ach receptor hyperthermia, flushing, dilated pupil, ileus
![Page 11: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/11.jpg)
SSRI
FLUOXETINE
PAROXETINE
SERTRALINE
CITALOPRAM
![Page 12: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/12.jpg)
SSRI MOA
SEROTONIN SPECIFIC REUPTAKE INHIBITORS
CLINIC USE:DEPRESSION, OCD,BULIMIA, SOCIAL PHOBIAS, PTSD
![Page 13: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/13.jpg)
SNRI
• INHIBIT SEROTONIN AND NE REUPTAKE
• CLINICAL USE: DEPRESSIONo VENLAFAXINE CAN ALSO BE USED FOR
GENERALIZED ANXIETY DISORDERo DULOXETINE ALSO INDICATED FOR DIABETIC
PERIPHERAL NEUROPATHY
![Page 14: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/14.jpg)
![Page 15: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/15.jpg)
![Page 16: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/16.jpg)
MAO INHIBITORS
TRANYLCYPROMINE
PHENELZINE
ISOCARBOXAZID
SELEGILINE
MOA:NONSELECTIVE MAO INHIBITION WHICH WILL INCREASE LEVELS OF AMINE NT
![Page 17: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/17.jpg)
MAOI
CLINICAL USE:
ATYPICAL DEPRESSION
ANXIETY
HYPOCHONDRIASIS
HYPERSOMNIA
![Page 18: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/18.jpg)
![Page 19: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/19.jpg)
ATYPICAL ANTIDEPRESSANTSBUPROPION
INCREASE NE DA
TOXICITY(STIMULANT EFFECT)
TACHYCARDIA, INSOMNIA, HEADACHE, SEIZURE IN BULIMIC PATIENTS
MIRTAZAPINE
A2-ANTAGONIST:INCREASE RELEASE OF NE AND 5ST
POTENT 5ST2 AND 5ST3 ANTAGONIST
SE:SEDATION, INCREASED APPETITE, WEIGHT GAIN, DRY MOUTH
![Page 20: antidepressant powerpoint on pharmacology](https://reader034.vdocuments.mx/reader034/viewer/2022042507/55cf948c550346f57ba2c2e2/html5/thumbnails/20.jpg)
MAPROTILINE
BLOCKS NE REUPTAKE
SE:SEDATION, ORTHOSTATIC HYPOTENSION
TRAZODONE
INHIBITS 5ST REUPTAKE
USED FOR INSOMNIA
SE: SEDATION, NAUSEA, PRIAPISM, POSTURAL HYPOTENSION